American Bio Medica Corporation
ABMC · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -1.8% | -20.1% | 13% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 45.1% | -83.8% | -4.3% | -39.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Income | -$0 | -$1 | -$0 | -$0 |
| % Margin | -129.3% | -743.7% | -125.4% | -187.6% |
| Other Income/Exp. Net | $2 | $1 | -$0 | -$0 |
| Pre-Tax Income | $2 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $4 | -$0 | -$0 | -$0 |
| % Margin | 2,410.4% | -189.8% | -175.1% | -216.2% |
| EPS | 0.082 | -0.007 | -0.008 | -0.008 |
| % Growth | 1,345.5% | 13.2% | 8.4% | – |
| EPS Diluted | 0.082 | -0.007 | -0.008 | -0.008 |
| Weighted Avg Shares Out | 48 | 48 | 48 | 48 |
| Weighted Avg Shares Out Dil | 48 | 48 | 48 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $2 | -$0 | -$0 | -$0 |
| % Margin | 1,164.6% | -157.5% | -119.1% | -180% |